EVMN

Evommune, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. The company's lead product candidate is designed to modulate immune responses through a novel mechanism of action targeting specific pathways involved in autoimmune conditions. Evommune's approach aims to provide effective treatment while minimizing the immunosuppression and safety concerns associated with existing therapies. The company is advancing its pipeline through clinical development with a focus on conditions with significant unmet medical needs. Evommune represents an innovative approach to treating autoimmune diseases through targeted oral immunomodulation.